Navigation Links
Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors

DANBURY, Conn., June 11 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Barry Ginsberg, M.D., Ph.D., has been elected as a new member of its Board of Directors, effective June 10, 2008. Dr. Ginsberg is currently Chief Executive Officer of Diabetes Technology Consultants where he advises Fortune 500 companies in the field of diabetes.

"We are pleased to welcome Barry to our Board of Directors at such an important time for Biodel," stated Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Barry's diabetes expertise and experience as a seasoned advisor to commercial stage companies will provide invaluable insights and contributions to Biodel as we prepare to file VIAject(TM)'s New Drug Application by the end of 2008."

Dr. Ginsberg joins the Company's Board of Directors with over 25 years of experience in diabetes. Prior to Diabetes Technology Consultants, Dr. Ginsberg served as Vice President of Worldwide Medical Affairs in the Diabetes HealthCare Division at Becton Dickinson during his 17 year tenure. Dr. Ginsberg currently serves as Chairman of the Scientific Advisory Boards at Agamatrix and Therafuse, and is a Scientific Advisory Board Member at Covidien, Metacure, Glucolight and Becton Dickinson Diabetes HealthCare. While a Professor of Medicine at the University of Iowa (1977-90), he was a Principal Investigator of the prestigious Diabetes Control and Complications Trial.

Biodel also announced that Albert Cha, M.D., Ph.D. will depart from the Company's Board of Directors. Dr. Cha, a Managing Partner of Vivo Ventures, joined the Company's Board of Directors in July 2006.

"Albert has been a valued source of counsel and he served our Company and its shareholders well during our transition from an early stage private company to a public company with a late stage Phase III product candidate. We thank him for his service and wish him well," stated Dr. Steiner.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at


SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
4. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
5. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
6. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
7. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
8. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
9. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
10. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
11. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
Post Your Comments:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
Breaking Biology News(10 mins):